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Objective: The relative differences in effectiveness of subchondral stimulation, osteochondral grafts, and
autologous chondrocyte implantation (ACI) are still unclear. It is the objective of this study to system-
atically review the literature on ACI compared to other treatments by clinical outcome and the quality of
the repair tissue, including an assessment of the validity of these ﬁndings.
Method: The online databases PubMed, EMBASE, Cochrane Controlled Trial Register, CENTRAL, CINAHL,
and BioMed were searched. Controlled trials comparing ACI with other methods of cartilage repair or
placebo were included. Data on clinical outcome and the quality of the repair tissue was abstracted in
duplicate. Study validity was assessed by individual components (randomization, blinded outcome
assessment, sample size, attrition, percentage biopsies).
Results: Nine studies were included. The internal validity of most of these studies was poor. Studies
comparing ACI with subchondral stimulation have a higher quality and show no differences in clinical
outcomes, but suggest better results in tissue quality. The high quality evidence comparing ACI with
osteochondral grafts shows better clinical outcomes and higher tissue quality after ACI.
Conclusion: Among the included studies there is much inconsistency in methodological quality and
ﬁndings. Regardless of these problems, the absolute differences between groups are fairly small, thus
raising questions about their clinical importance. Future studies will be needed to answer the question of
beneﬁts of ACI compared to other treatments, and could proﬁt from addressing and avoiding the
problems seen in this group. Finally conclusions concerning long-term effects are still difﬁcult.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Recently, biological regeneration has become popular in patient
management in osteoarthritis, primarily to account for the ever-
growing population of younger and more active patients. Current
estimates of the prevalence of focal cartilage defects of the knee
range from 5% to 11% in young patients and up to 60% in older
patients1e3. Gerber et al.4 followed 1321 patients with joint injuries
over 36 years on average and found 13.9% progressed to fully
developed knee osteoarthritis by the age of 65, with a signiﬁcant
5.2 fold increase in risk compared to controls. Although there is
considerable variation in the time interval between the occurrence: P. Vavken, Department of
arvard Medical School, 300
, USA. Tel: 1-617-919-2105;
du (P. Vavken).
s Research Society International. Pof focal cartilage defects and the onset of osteoarthritis, there is
a large proportion of younger patients suffering from cartilage
defects and likely to develop osteoarthritis. Due to their young age
and unabated demand for high mobility, these patients do not
respond optimally to total joint replacement. Biological repair is the
most valuable option to address the needs of this population. Two
parameters describe the success of such procedures: the immediate
clinical effect and the quality of the repair tissue as a predictor of
the longevity of results.
The available options in biological repair for cartilage defects of
the knee are (1) subchondral marrow stimulation5,6, (2) osteo-
chondral graft transfer7, and (3) autologous chondrocyte implan-
tation (ACI)8. Among these, ACI is technically most advanced and
holds much promise for true healing rather than ﬁbrous scarring;
however, such assumptions warrant robust evidence. A number of
randomized controlled trials have been conducted to compare ACI
with the abovementioned other options in cartilage repair, but have
shown fairly inconsistent results9. Furthermore, both the design
and conduct of some of these trials have been criticized and theublished by Elsevier Ltd. All rights reserved.
Initial online search produced 367 results 
MEDLINE   n=164 
EMBASE   n=50 
CINAHL  n=68 
BioMed  n=64 
Cochrane CCTR   n=21 
n=238 obtained and reviewed for eligibility 
n=10 included in analysis 
n=129 excluded: duplicates in results 
n=102 excluded: not randomized, controlled trials 
n=3 excluded: animal studies 
n=3 excluded: comparing different forms of ACI 
n=121 excluded: not focusing on cartilage defects, 
not including ACI as treatment group 
n=1 included: identified in hand search 
Fig. 1. Trial ﬂow.
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various randomized controlled trials with sufﬁciently long follow-
up were published11,12. Some of these trials were pooled in a recent
systematic review, but only clinical outcome, not quality of repair
tissue or study validity, was considered13.
In an effort to further assess the evidence of options in cartilage
repair of the knee, our study was multifaceted. Our ﬁrst objective
was to address a systematic review of the evidence for the short-
and long-term efﬁcacy of ACI compared to subchondral marrow
stimulation and osteochondral graft transfer, as measured by clin-
ical effect and repair tissue quality. The second objective was to
assess the quality of published trials and in a comparative context
to the validity of the ﬁndings presented in the existing literature.
Methods
Search strategy
Online searches of the databases PubMed, EMBASE, Cochrane
Controlled Trial Register, CENTRAL, CINAHL, and BioMed were
performed. Brieﬂy, the terms “autologous chondrocyte implanta-
tion”, “autologous chondrocyte transplantation” and “knee” were
combined without restrictions concerning language or date of
publication. See the Appendix for full description of the search
algorithms. These results were searched for controlled trials using
a highly sensitive and validated ﬁlter, and reviewed by hand for
eligible studies14,15. The bibliographies of relevant papers were
searched for further studies. All searches were concluded by
December 2009.
Study selection
All controlled trials comparing ACI with another treatment or
placebo in humans with a minimal follow-up of 6 months were
eligible for inclusion. Studies were included if the treatment group
received ACI of any type for a cartilage defect in the knee compared
to a group receiving another cartilage repair procedure or placebo.
Procedures addressing the pathogenesis of the cartilage defect in
individual patients, such as malalignment or instability, were not
considered exclusion criteria. Case reports, case series, retrospec-
tive studies, non-randomized controlled trials, and studies
systematically focusing on the combined efﬁcacy of ACI and other
major procedures, such as meniscus replacement, were excluded
from further review.
Data abstraction
Data were abstracted for the endpoints clinical outcome,
reported in any form at 1 year of follow-up and at the latest follow-
up, and quality of repair tissue (in arthroscopic and histological
assessment and as description of failures). Also, parameters perti-
nent for validity assessment and demographics of the studied
populations were abstracted. All data were independently extrac-
ted twice and cross-checked for errors.
Validity assessment
Level-of-evidence was determined for all included studies (as
given on www.ejbjs.org). Internal validity was assessed by the
following components: appropriateness of randomization proce-
dure (yes/no), blinding of outcome assessment (yes/no), a priori
sample size calculation (yes/no), attrition reported and accounted
for in analysis (yes/no), and percentage of biopsies. Appropriate
randomization was deﬁned as computer-generated sequences or
random number tables, with concealed allocation via opaqueenvelopes or an independent referee, or equivalent methods.
Alternating allocation, allocation based on date, or other predict-
able methods were considered inappropriate. The use of composite




Our literature search produced 367 papers in online databases
and one in hand searches. After exclusion of duplicates 238 were
reviewed for eligibility. Seven level-I (high quality) and eII (low
quality, i.e., <80% follow-up, improper randomization, no blinding)
randomized controlled trials, published in 10 papers, were
included11,12,17e24. A subgroup from one of the included trials12 was
published independently25, but this paper was not included since
outcomes for the whole population are given in the ﬁrst publica-
tion12. Details of search results are illustrated in Fig. 1. All included
studies were published between 2000 and 2008 in English or
German and compared different subtypes of ACI with osteochon-
dral allografts (n¼ 4) or subchondral marrow stimulation (n¼ 5) in
a total of 526 patients (Table I).
Clinical outcome
Comparing ACI with microfracture Saris et al. found no differ-
ence in KOOS scores, based on a minimal difference of 9% between
95% CI at 24 months, but signiﬁcantly better outcomes for ACI at 36
months. Knutsen et al. found no signiﬁcant difference in functional
scores at 2 or 5 years either, but a signiﬁcantly better result in the
physical component of the SF-36 for microfracture. Basad found
better results for ACI compared with microfracture on the Meyers,
Lysholm, Tegner, and ICRS score, but presents no statistical infer-
ence with his preliminary results. Visna et al., comparing
Table I
Characteristics of included studies






Horas et al.21 2000 40 (20/20) Osteochondral
autograft transfer
Subjective outcome, Lysholm, Tegner,
Meyer, MRI, histology, IHC, electron microscopy
24 4.4 23/17
Horas et al.20 2003 40 (20/20) Osteochondral
autograft transfer
Lysholm, Tegner, Meyer, histology, IHC 24 3.9/3.6 23/17
Bentley et al.17 2003 100 (58/42) Osteochondral
autograft transfer
Modiﬁed Cincinnati and Stanmore, histology 19 4.66 57/43
Dozin et al.19 2005 34 (22/22) Osteochondral
autograft transfer
Lysholm, IKDC 25 2.0/1.9 27/17
Knutsen et al.22 2004 80 (40/40) Microfracture Lysholm, SF-36, Tegner score, ICRS, histology 24 5.1/4.5 48/32
Knutsen et al.11 2007 80 (40/40) Microfracture ICRS, Lysholm, SF-36, Tegner 60 5.1/4.5 48/32
Basad et al.24 2004 19 (10/9) Microfracture Meyers, Lysholm, Tegner, ICRS 12 3.8/4.2 e
Saris et al.23 2008 118 (57/61) Microfracture Histology, KOOS, safety 18 2.6/2.4 76/42
Saris et al.12 2009 85 (41/44) Microfracture MRI (MOCART), KOOS, safety 36 2.6/2.4 e
Visna et al.18 2004 50 (25/25) Abrasion Lysholm, IKDC, Tegner, ICRS, histology 12 4.1/3.4 34/16
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Lysholm, IKDC, and Tegner scores for patients treatedwith ACI at 12
months.
Bentley et al. compared ACI with osteochondral grafts and found
no difference in combined good and excellent results, although
there were 23 excellent results with ACI and only nine with OAT at
19 months on average. Horas et al., too, compared ACI with osteo-
chondral grafting, and found no signiﬁcant difference in outcomes
on clinical scores at 2 years, but reported on a slower increase in
scores with ACI. Dozin et al., in his study troubled by patient
compliance and attrition, found no signiﬁcant differences in clinical
outcome, either. Clinical outcome is summarized in Table II.
Quality of repair tissue
The quality of repair tissue was assessed arthroscopically in six
studies, using the ICRS score or descriptive assessment26. A
systematically performedmorphological assessment during second
look arthroscopies was done by Bentley et al. and Knutsen et al. to
compare ACI with osteochondral grafts or microfracture in 60% and
84% of their patients, respectively. While Knutsen et al. observed no
difference in ICRS scores for ACI and microfracture at 2 years,
Bentley et al. saw a signiﬁcantly better result after ACI at 1 year.
Horas et al. reported on second look arthroscopies in six ACI casesTable II
Clinical and histological outcomes among included studies
ACI vs Author Year Clinical outcome His
Osteochondral
autograft transfer








Bentley et al.17 2003 88% good and excellent
after ACI, 69% after OAT
82%
34%
Dozin et al.19 2005 Complete recovery in 68%
after ACI, 88% after OAT
No
Microfracture Basad et al.24 2004 ACI had better results
in clinical scores
No
Knutsen et al.22 2004 No differences in Lysholm
scores, MFX better in SF-36
No
wit
Knutsen et al.11 2007 No differences in scores,
no more difference in SF-36
No
Saris et al.23 2008 No difference Bet
Saris et al.12 2009 Improvement after
ACI better than MFX
No
Abrasion Visna et al.18 2004 ACI superior Noand three OAT cases after a maximum follow-up of 21 months (23%
of all included patients), but did not see differences in repair tissue.
However, he found persistent gaps around the graft, an observation
supported by Bentley et al. Visna et al. followed four patients from
his ACI group arthroscopically and found two sufﬁciently healed
defects and two failures.
A systematic, comparative, histological assessment of biopsies
was done by Saris et al. and Knutsen et al. for ACI compared with
microfracture, and by Bentley et al. comparing ACI with osteo-
chondral grafts. Saris et al. found signiﬁcantly better results after
ACI. Knutsen et al. found no signiﬁcant difference in the frequency
of hyaline-like repair tissue after ACI or microfracture, although
there seems to be at least a borderline signiﬁcance at P¼ 0.08.
More importantly there was no association between histology and
clinical outcome at 2e and 5 years. However, there was a signiﬁ-
cant association between poor macroscopic outcome and the
likelihood of failure, and an unclear association between failures
and poor histology. Bentley et al., in turn, found a signiﬁcant
superiority of ACI over osteochondral grafting in histological
analysis. Horas et al. reported no differences in histological,
immunohistochemical, and electron-microscopic analyses of
patients after ACI and osteochondral grafting, but only in a rather
small proportion of cases (23%). Histological outcomes are
summarized in Table II.tological outcome Conclusion
rocartilaginous defect ﬁlling in ACI,
visible changes in tissue after OAT
Prefer OAT over ACI
rocartilaginous defect ﬁlling in ACI,
visible changes in tissue after OAT
Prefer OAT over ACI
good and excellent after ACI,
after OAT
“.a signiﬁcant superiority of ACI
over mosaciplasty. ”
histology “.although low power. ACI and
mosaicplasty are. clinically equivalent.”
histology “good and very good clinical results.
only a temporary assessment.”
difference, no association
h clinical outcome
“.Mid-term and long-term follow-up
is needed to determine if one
method is better.”
histology “.no signiﬁcant difference in the clinical
and radiographic results.”
ter results for ACI “.tissue regenerate that was superior
to that after microfracture.”
histology “ACI . results in signiﬁcantly better
clinical outcome after 36 months.”
histology “.better outcome in patients
treated with ACI.”
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ACI and microfracture after 36 months, although there was more
subchondral plate elevation in microfractured patients. Horas
reported bone marrow edema on MRI persisting for 12 months
after ACI andmosaicplasty. By 24months in ACI patients the edema
had resolved and the defect showed a homogenous repair tissue,
yet with T2 hyperintensity. Twenty-four months after mosaicplasty
Horas reported irregular signaling at the osseous interfaces and
hypointense T1 signals for the bone plug.
For microfracture vs ACI, Knusten reported nine failures each
after 5 years of follow-up. In his study, 25% of the ACI cases
underwent debridement compared to 10% of the microfractured
patient. Saris reported similar numbers with 25% of his ACI cases
developing cartilage hypertrophy compared to 13% of the micro-
fractured cases. Overall, Saris et al. observed 67% and 59% adverse
events in ACI and microfracture, respectively, but only 9% and 13%
serious events for ACI and microfracture. For mosaicplasty, Bentley
et al. reported four failed treatments inwhich the plugs were in situ
but no tissue had formed in between and three cases in which the
plugs had disintegrated. Horas reported to have seen gaps between
the plugs and adjacent cartilage in all second look arthroscopies.Validity assessment
Assessment of study validity revealed rather insufﬁcient results for
most studies. Detailed results are given in Table III. Brieﬂy, there is
reason to question the internal validity of theﬁndings inmost studies.
Power analyses and sample size calculationswere not done inﬁve out
of nine studies, and sample size was not adjusted for multiple testing
in any, although up to eight endpoints were analyzed in parallel.
Randomization was adequate in most studies, except in the two
studies by Horas et al., who allocated patient alternately in order of
presentation, thus in a highly predictable manner. Allocation
concealment was insecure in all studies, and successful blinding of
patients is unlikely, since ACI requires a second operation and OAT or
microfracture do not. Also, while microfracture and osteochondral
grafting is performed arthroscopically, ACI is an open procedure
leaving a scar, thus making concealment of allocation during clinical
examination difﬁcult. Horas et al. report that all their patients were
informed about their allocation status and offered the option to
change their allocation. These facts strongly suggest a potential for
considerable bias. Histological outcome assessment was reportedly
blinded in most cases, but it often remained unclear whether clinical
outcome assessment was blinded, too. Attrition rates for clinical
outcome assessment were fairly, if not surprisingly, low in most
studies, but in the paper published by Dozin et al. Most alarmingly,
however, were attrition rates in arthroscopic and histological assess-
ment, the secondaryoutcomes of this studyand themain variables for
prediction of long-term outcomes. Also, these facts suggest that there
might be severe bias insofar as patients with beneﬁcial outcomes didTable III
Quality parameters of included studies
Author Year Sample size Randomization procedure Blinding of a
Horas et al.21 2000 No Alternating consecutive Histology
Horas et al.20 2003 No Alternating consecutive Histology
Bentley et al.17 2003 No Not speciﬁed Unclear
Dozin et al.19 2005 Yes Coordinating center Surgeon ass
Knutsen et al.22 2004 Yes Sealed envelopes Histology an
Knutsen et al.11 2004 No Not speciﬁed Surgeon ass
Basad et al.24 2007 Yes Sealed envelopes Primary inve
Saris et al.23 2008 Yes Minimization Histology, cl
Saris et al.12 2009 Yes Minimization MRI, clinical
Visna et al.18 2004 No Sealed envelopes Not speciﬁed
* Of required sample size.
y As delineated by JBJS-A.not present for follow-up, and only those with poor outcomes
answered to the invitation for follow-up and were included in the
analysis. Among those studies reporting analyses of histological data,
only one study included at least 80%of patients for such assessment22,
and only three studies includedmore thanhalf of their patients17,22,23.Discussion
It was the objective of this review to assess the current evidence
for the efﬁcacy of ACI compared to other methods of cartilage
repair. As a second objective, we wanted to analyze the validity of
the included studies and their ﬁndings, to make sure our inter-
pretations are accurate. Given the substantial heterogeneity among
the included studies it is not sensible to perform a quantitative data
analysis to present a meta-analysis of the data.
In direct comparison of clinical outcomes there seems to be
valid and reliable evidence for equivalent outcomes after ACI and
microfracture in the short-term, based on the high-quality studies
by Knutsen and Saris. Concerning osteochondral grafting, Bentley
presented strong evidence for a higher efﬁcacy of ACI. Finally,
Gudas et al. presented ﬁndings suggesting that mosaicplasty has
better outcomes than microfracture27. However, problems in the
clinical assessment are the rather short follow-up periods, and,
maybe more importantly, the choices of instruments. Sackett
pointed out the necessity to use validated questionnaires speciﬁc
for the condition being studied28. Hambley et al. and Tanner et al.
studied the reliability of different scores for articular cartilage
repair and reported that primarily the IKDC and secondly the KOOS
give the most accurate description of symptoms and disabilities
experienced by patients29,30. The ICRS score, too, was speciﬁcally
designed and validated to study cartilage injuries and repair26. The
Lysholm score has been shown to be valid for chondral defect
treatment after modiﬁcation and with some exceptions31,32. The
reported Meyers, and modiﬁed Cincinnati scores still await vali-
dation for ACI. Thus, only six out of nine studies reported on
cartilage-speciﬁc scores, and only four used a validated instrument.
This runs in parallel to the question whether follow-ups were
sufﬁciently long for valid clinical assessment or deﬁnitive conclu-
sions about tissue differentiation. It has been shown that outcome
after ACI improves signiﬁcantly over the ﬁrst 2 years, and that there
is still some improvement during the third postoperative year33.
Only Knutsen reported on results at more than 2 years, although
both Basad and Horas planned to so11,21. Also, it has been shown
that the outcome in patients undergoingmicrofracture deteriorates
from 18 to 36 months, suggesting failure of the repair tissue34.
There seems to be a general trend for higher quality of repair
tissue after ACI, suggesting better long-term results when
compared to microfracture and osteochondral grafts. There are two
reasons for better results after ACI: ﬁrst of all the capacity of ACI to




essed outcomes 15.9% (26.75)* No Bx II
d clinical 0% 84% I
essed all 0% No Bx I
stigator assessed all 0% No Bx I
inically self-assessed 17% 73% I
ly self-assessed 28% No Bx II
0% 8% II
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fracture (up to 27e33% incidence in MRI follow-up studies)5,34,35
and persistent gaps between osteochondral grafts and the adja-
cent cartilage17,20. However, there are some potential problems
associated with prediction of long-term outcome based on histo-
logical assessment, since the selection of individuals for such
analysis was problematic at best in most of the included studies.
Although it is understandable that investigators, surgeons, have
compunction about jeopardizing outcomes by taking biopsies and
thus disrupting the treasured repair tissue, but this must not lead to
assessing only those patients in need of reoperation because of
treatment failures. Yet it seems this happened quite frequently, as
only one study assessed at least 80% of participants. Finally, Knut-
sen quite unexpectedly found no association between histological
ﬁndings at 2 years and clinical outcome at 5 years, although he did
ﬁnd a signiﬁcant association between macroscopic quality and
likelihood of failure11. These ﬁndings suggest that a high quality
repair cannot guarantee excellent clinical outcome, but that poor
quality tissue will lead to clinical failure. This interpretation is
supported by results presented by Henderson and colleagues, who
were able to show that hyaline repair tissue had better outcomes in
biomechanical testing, whereas ﬁbrocartilaginous repair was
associated with persisting symptoms in the affected joint36. In
future studies it might be reasonable to use MRI, a non-invasive,
non-destructive instrument that has been shown to be capable of
monitoring cartilage maturation, to supplement or even replace
histological outcome assessment37e39.
One important point in systematically reviewing evidence is the
validity of the included ﬁndings. The rather low overall methodolog-
ical quality of most cartilage repair studies, and their propensity to
bias, has been documented before10. This poses a direct threat to our
study, thus we studied the validity of the included studies explicitly.
From what has been reported it seems that there are signiﬁcant
differences inpatient populations concerning defect size and speciﬁcs
of treatment, raising questions about selection bias and external val-
idity of the reported ﬁndings. Defect sizes are of particular concern,
since there is considerable variation, and small defects are known to
respond favorably to almost any treatment or might even become
asymptomatic without treatment e as has been seen by Dozin19.
Furthermore, high attrition rates, often insufﬁcient randomization,
and uncertainty about blinding of observers engender concerns about
internal validity. In addition to high attrition rates, only four studies
report on sample size calculations, and none adjusted for multiple
testing, raising further questions concerning power. However, it
should not go unnoticed that these observations build only on what
has been reported,which is not necessarily the same aswhat hasbeen
done40. Finally, during the time in which the included studies were
performed, the ACI technique evolved considerably. Not only were
biomaterials introduced into theﬁeld, eliminating such complications
as hypertrophy while reducing the technical complexity of the
procedure41, but surgeons also increased their understanding of the
multi-factorial nature of cartilage defects. Once such problems as
instability and malalignment were addressed appropriately, even
“impossible locations” such as patellar defects could be successfully
treated with ACI42,43. These developments are only inadequately
reﬂected in the existing randomized controlled trials. However, these
developments have also led us to put thought into the notion how
much of the reported improvement is afforded by to the actual
cartilage repair, and how much due to “ancillary measures”. In
summary, these ﬂawsmight very well have caused serious bias in the
current cartilage repair literature, the size of which unfortunately
cannot be estimated. Future studies should consider these facts and
avoid such ﬂaws in their design phase.
Previous studies reviewed the evidence for ACI or cartilage
repair, but without coming to deﬁnitive conclusions9,44e46.However, this study encompasses more primary trials than any
other thus far published, also because it included non-English
language studies too. However, there are some shortcomings
associated with this study. Despite a comprehensive search
strategy, relevant studies might have been overseen, but given the
popularity of ACI this seems unlikely. Also, as mentioned above, all
interpretations presented in this study derive from published
information, and important details concerning study design might
have been omitted for the sake of publication length, or because
they were deemed not interesting enough for presentation to an
orthopedic audience. It should also be noticed that in this ﬁeld of
medicine it is difﬁcult to follow study design recommendations,
since double-blinding is nearly impossible unless all patients
undergo two operations, which is ethically difﬁcult. Also ACI can
hardly be seen as one, standardized treatment, due to technical
differences, and inter-patient variation in cell quality. This fact has
been addressed by Saris and Basad by imposing strict quality
controls on their in-vitro cell processing units23,24. Beyond control,
however, is the patients biological response to implanted cells.
Conclusion
In conclusion, no clear recommendation concerning the efﬁcacy
of ACI compared to the treatment options microfracture or osteo-
chondral grafts can be deducted from the existing literature. There
is some evidence for better clinical outcomes for ACI compared
with osteochondral grafts and equivalent outcomes compared with
microfracture in those studies with high internal validity. Addi-
tionally and in combination with other studies on microfracture, it
seems that there truly is evidence for a higher quality in repair
tissue after ACI than with other procedures, and there is reason to
believe that this high quality will be relevant for improving the
longevity of effects. It is important to note that the absolute
differences between treatment groups, regardless of signiﬁcance,
are mostly rather small, thus raising the question of clinical
importance beyond mere statistical signiﬁcance.
Conﬂict of interest




#1 Search “autologous chondrocyte implantation”
#2 Search “autologous chondrocyte transplantation”
#3 Search “knee”
#4 Search #1 or #2
#5 Search #3 and #4
#6 Search (((randomized controlled trial) OR (controlled clinical
trial) OR (randomized controlled trial[mh]) OR (random allo-
cation[mh]) OR (double-blind[mh]) OR (single-blind[mh]))
NOT (animal[mh] NOT human[mh])) OR (((clinical trial) OR
(clinical trials[mh]) OR (“clinical trial”[tw]) OR (((“singl*”[tw])
OR (“doubl*”[tw]) OR (“treb*”[tw]) OR (“tripl*”[tw])) AND
(mask*[tw] OR blind*[tw])) OR (“latin square”[tw]) OR
(placebos[mh]) OR (placebo*[tw]) OR (random*[tw]) OR
(research design[mh:noexp])) NOT (animal[mh] NOT human
[mh])) OR ((((comparative study[mh]) OR (evaluation studies
[mh]) OR (evaluation studies[mh]) OR (follow-up studies[mh])
OR (prospective studies[mh]) OR (cross-over studies[mh]) OR
(control*[tw]) OR (prospectiv*[tw]) OR (volunteer*[tw])) NOT
(animal[mh] NOT human[mh])) NOT ((((clinical trial) OR
(clinical trials[mh]) OR (“clinical trial”[tw]) OR (((“singl*”[tw])
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(mask*[tw] OR blind*[tw])) OR (“latin square”[tw]) OR
(placebos[mh]) OR (placebo*[tw]) OR (random*[tw]) OR
(research design[mh:noexp])) NOT (animal[mh] NOT human
[mh])) OR (((randomized controlled trial) OR (controlled clin-
ical trial) OR (randomized controlled trial[mh]) OR (random
allocation[mh]) OR (double-blind[mh]) OR (single-blind[mh]))
NOT (animal[mh] NOT human[mh]))))
#7 Search #5 and #6
EMBASE, CCTR, BIOSIS, CLHTA, CINAHL via Ovid
1. Clinical trial/
2. Randomized controlled trial/
3. Randomization/
4. Single blind procedure/
5. Double blind procedure/
6. Crossover procedure/
7. Placebo/





13. (allocated adj2 random).tw.
14. Single blind$.tw.
15. Double blind$.tw.






22. Abstract report/or letter/
23. or/20e22
24. 19 not 23
25. animal/not human/
26. 24 not 25
27. “autologous chondrocyte implantation”.mp.
28. “autologous chondrocyte transplantation”.mp.
29. exp KNEE/
30. 27 or 28
31. 30 and 29
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